Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 2
1988 3
1989 1
1990 2
1991 2
1992 2
1994 1
1995 2
1996 3
1997 3
1998 1
1999 2
2000 2
2001 1
2003 2
2005 1
2006 2
2007 4
2008 3
2010 1
2011 1
2012 1
2013 3
2014 2
2015 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Perspectives of taste reception.
Avenet P, Lindemann B. Avenet P, et al. J Membr Biol. 1989 Nov;112(1):1-8. doi: 10.1007/BF01871158. J Membr Biol. 1989. PMID: 2687472 Review. No abstract available.
Preclinical profile of befloxatone, a new reversible MAO-A inhibitor.
Curet O, Damoiseau-Ovens G, Sauvage C, Sontag N, Avenet P, Depoortere H, Caille D, Bergis O, Scatton B. Curet O, et al. Among authors: avenet p. J Affect Disord. 1998 Dec;51(3):287-303. doi: 10.1016/s0165-0327(98)00225-0. J Affect Disord. 1998. PMID: 10333983 Review.
Cellular basis of taste reception.
Avenet P, Kinnamon SC. Avenet P, et al. Curr Opin Neurobiol. 1991 Aug;1(2):198-203. doi: 10.1016/0959-4388(91)90078-l. Curr Opin Neurobiol. 1991. PMID: 1821182 Review.
SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms.
Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Depoortere H, Françon D, Avenet P, Schoemaker H, Evanno Y, Sevrin M, George P, Scatton B. Griebel G, et al. Among authors: avenet p. CNS Drug Rev. 2003 Spring;9(1):3-20. doi: 10.1111/j.1527-3458.2003.tb00241.x. CNS Drug Rev. 2003. PMID: 12595909 Free PMC article. Review.
Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia.
Boulay D, Pichat P, Dargazanli G, Estenne-Bouhtou G, Terranova JP, Rogacki N, Stemmelin J, Coste A, Lanneau C, Desvignes C, Cohen C, Alonso R, Vigé X, Biton B, Steinberg R, Sevrin M, Oury-Donat F, George P, Bergis O, Griebel G, Avenet P, Scatton B. Boulay D, et al. Among authors: avenet p. Pharmacol Biochem Behav. 2008 Nov;91(1):47-58. doi: 10.1016/j.pbb.2008.06.009. Epub 2008 Jun 24. Pharmacol Biochem Behav. 2008. PMID: 18621075
Effects of the beta3-adrenoceptor (Adrb3) agonist SR58611A (amibegron) on serotonergic and noradrenergic transmission in the rodent: relevance to its antidepressant/anxiolytic-like profile.
Claustre Y, Leonetti M, Santucci V, Bougault I, Desvignes C, Rouquier L, Aubin N, Keane P, Busch S, Chen Y, Palejwala V, Tocci M, Yamdagni P, Didier M, Avenet P, Le Fur G, Oury-Donat F, Scatton B, Steinberg R. Claustre Y, et al. Among authors: avenet p. Neuroscience. 2008 Oct 2;156(2):353-64. doi: 10.1016/j.neuroscience.2008.07.011. Epub 2008 Jul 11. Neuroscience. 2008. PMID: 18691638
Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.
Depoortère R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, Poncelet M, Heaulme M, Santucci V, Decobert M, Cudennec A, Voltz C, Boulay D, Terranova JP, Stemmelin J, Roger P, Marabout B, Sevrin M, Vigé X, Biton B, Steinberg R, Françon D, Alonso R, Avenet P, Oury-Donat F, Perrault G, Griebel G, George P, Soubrié P, Scatton B. Depoortère R, et al. Among authors: avenet p. Neuropsychopharmacology. 2005 Nov;30(11):1963-85. doi: 10.1038/sj.npp.1300772. Neuropsychopharmacology. 2005. PMID: 15956994
44 results